Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;11(6):1578-1586.
doi: 10.1111/1759-7714.13432. Epub 2020 Apr 14.

Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

Kei Sonehara  1 , Kazunari Tateishi  1 , Masamichi Komatsu  1 , Hiroshi Yamamoto  1 , Masayuki Hanaoka  1
Affiliations

Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer

Kei Sonehara et al. Thorac Cancer. 2020 Jun.

Abstract

Background: The lung immune prognostic index (LIPI) is a marker that combines the derived neutrophil-to-lymphocyte ratio (dNLR) and serum lactate dehydrogenase (LDH) level and is a recently reported prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer (NSCLC). However, there are no reports regarding the prognostic value of LIPI in small cell lung cancer (SCLC).

Methods: We retrospectively enrolled 171 patients diagnosed with SCLC and treated at Shinshu University School of Medicine between January 2003 and November 2019. Progression-free survival (PFS) and overall survival (OS) were compared according to LIPI, and we investigated whether LIPI could be a prognostic factor in SCLC using the Kaplan-Meier method and univariate and multivariate Cox models.

Results: The median OS of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (21.0 vs. 11.6 months, P < 0.001). The multivariate analysis associated with OS indicated that LIPI 1 plus 2 was an independent unfavorable prognostic factor in addition to poor performance status (2-3), old age (≥ 75 years) and stage (extensive disease [ED]). However, PFS of the LIPI 0 group was not significantly different from that of the LIPI 1 plus 2 group. In ED-SCLC patients, the median PFS and OS of the LIPI 0 group were significantly longer than those of the LIPI 2 group (6.6 vs. 4.0 months, P = 0.006 and 17.1 vs. 5.9 months, P < 0.001, respectively).

Conclusions: We confirmed the prognostic value of LIPI in SCLC, especially ED-SCLC.

Key points: Significant findings of the study: The present study is the first to demonstrate that pretreatment lung immune prognostic index is an independent prognostic factor associated with overall survival for small cell lung cancer.

What this study adds: The utility of the lung immune prognostic index as a prognostic factor for small cell lung cancer.

Keywords: Derived neutrophil-to-lymphocyte ratio; lung immune prognostic index; prognostic factor; serum lactate dehydrogenase; small cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier curves according to the lung immune prognostic index (LIPI) in small cell lung cancer (SCLC) patients. (a) The median progression‐free survival (PFS) of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (7.6 months vs. 5.6 months, respectively, P = 0.020) (formula image ) LIPI 0 group, (formula image ) LIPI 1 plus 2 group. (b) The median overall survival (OS) of the LIPI 0 group was significantly longer than that of the LIPI 1 plus 2 group (21.0 months vs. 11.6 months, respectively, P < 0.001) (formula image ) LIPI 0 group, (formula image ) LIPI 1 plus 2 group.
Figure 2
Figure 2
Kaplan‐Meier curves according to the lung immune prognostic index (LIPI) in LD‐SCLC patients. (a) The median progression‐free survival (PFS) of the LIPI 0 group was not significantly different from that of the LIPI 1 plus 2 group (11.2 months vs. 7.6 months, respectively, P = 0.397) (formula image ) LIPI 0 group, (formula image ) LIPI 1 plus 2 group. (b) The median overall survival (OS) of the LIPI 0 group was not significantly different from that of the LIPI 1 plus 2 group (25.5 months vs. 15.6 months, respectively, P = 0.383) (formula image ) LIPI 0 group, (formula image ) LIPI 1 plus 2 group.
Figure 3
Figure 3
Kaplan‐Meier curves according to the lung immune prognostic index (LIPI) in ED‐SCLC patients. (a) The median progression‐free survival (PFS) of the LIPI 0 group and LIPI 1 group was significantly longer than that of the LIPI 2 group (6.6 months vs. 4.0 months, P = 0.006 and 5.5 months vs. 4.0 months, P = 0.015, respectively) (formula image ) LIPI 0 group, (formula image ) LIPI 1 group, (formula image ) LIPI 2 group. The median PFS of the LIPI 0 group was not significantly different from that of the LIPI 1 group (P = 0.725). (b) The median overall survival (OS) of the LIPI 0 group was significantly longer than that of the LIPI 1 group and LIPI 2 group (17.1 months vs. 11.6 months, P = 0.009 and 17.1 months vs. 5.9 months, P < 0.001, respectively) (formula image ) LIPI 0 group, (formula image ) LIPI 1 group, (formula image ) LIPI 2 group. The median OS of the LIPI 1 group was significantly longer than that of the LIPI 2 group (P = 0.001).
See this image and copyright information in PMC

References

    1. Govindan R, Page N, Morgensztern D et al Changing epidemiology of small‐cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539–44. - PubMed
    1. Oronsky B, Reid TR, Oronsky A, Carter CA. What's new in SCLC? A review. Neoplasia 2017; 19: 842–7. - PMC - PubMed
    1. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small‐cell lung cancer: An analysis of the 2,580‐patient southwest oncology group data base. J Clin Oncol 1990; 8: 1563–74. - PubMed
    1. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune‐inflammation index, based on platelet counts and neutrophil‐lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015; 236: 297–304. - PubMed
    1. Suzuki R, Lin SH, Wei X et al Prognostic significance of pretreatment total lymphocyte count and neutrophil‐to‐lymphocyte ratio in extensive‐stage small‐cell lung cancer. Radiother Oncol 2018; 126: 499–505. - PMC - PubMed

MeSH terms

Substances